Literature DB >> 28662754

Animal Models of Ebolavirus Infection.

Marisa C St Claire1, Dan R Ragland2, Laura Bollinger2, Peter B Jahrling3.   

Abstract

Ebola virus is a highly pathogenic member of the family Filoviridae that causes a severe hemorrhagic disease in humans and NHP. The 2013-2016 West African outbreak has increased interest in the development and refinement of animal models of Ebola virus disease. These models are used to test countermeasures and vaccines, gain scientific insights into the mechanisms of disease progression and transmission, and study key correlates of immunology. Ebola virus is classified as a BSL4 pathogen and Category A agent, for which the United States government requires preparedness in case of bioterrorism. Rodents, such as Syrian golden hamsters (Mesocricetus auratus), mice (Mus musculus), and guinea pigs (Cavia porcellus), are the most common research species. However, NHP, especially macaques, are favored for Ebola virus disease research due to similarities with humans regarding the pathogenesis, clinical presentation, laboratory findings, and causes of fatality. To satisfy the regulatory requirements for approval of countermeasures against high-consequence pathogens, the FDA instituted the Animal Rule, which permits efficacy studies in animal models in place of human clinical data when such studies are not feasible or ethical. This review provides a comprehensive summary of various animal models and their use in Ebola virus disease research.

Entities:  

Mesh:

Year:  2017        PMID: 28662754      PMCID: PMC5482517     

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  99 in total

1.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells.

Authors:  K J Davis; A O Anderson; T W Geisbert; K E Steele; J B Geisbert; P Vogel; B M Connolly; J W Huggins; P B Jahrling; N K Jaax
Journal:  Arch Pathol Lab Med       Date:  1997-08       Impact factor: 5.534

3.  Baboon as a nonhuman primate model for vaccine studies.

Authors:  Krishna K Murthy; Mary T Salas; Kenneth D Carey; Jean L Patterson
Journal:  Vaccine       Date:  2005-08-25       Impact factor: 3.641

4.  Development of a preventive vaccine for Ebola virus infection in primates.

Authors:  N J Sullivan; A Sanchez; P E Rollin; Z Y Yang; G J Nabel
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

5.  Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.

Authors:  Thomas W Geisbert; Lisa E Hensley; Peter B Jahrling; Tom Larsen; Joan B Geisbert; Jason Paragas; Howard A Young; Terry M Fredeking; William E Rote; George P Vlasuk
Journal:  Lancet       Date:  2003-12-13       Impact factor: 79.321

6.  Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge.

Authors:  Kelly L Warfield; Dana L Swenson; Gene G Olinger; Warren V Kalina; M Javad Aman; Sina Bavari
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.

Authors:  Kelly L Warfield; John M Dye; Jay B Wells; Robert C Unfer; Frederick W Holtsberg; Sergey Shulenin; Hong Vu; Dana L Swenson; Sina Bavari; M Javad Aman
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

8.  Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates.

Authors:  Emily P Thi; Chad E Mire; Amy C H Lee; Joan B Geisbert; Joy Z Zhou; Krystle N Agans; Nicholas M Snead; Daniel J Deer; Trisha R Barnard; Karla A Fenton; Ian MacLachlan; Thomas W Geisbert
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 9.  Demand for nonhuman primate resources in the age of biodefense.

Authors:  Jean L Patterson; Richardo Carrion
Journal:  ILAR J       Date:  2005

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  22 in total

1.  Special Issue: Infectious Disease Research: Animal Models and Risk Management.

Authors:  Jason S Villano; Bryan E Ogden
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

2.  A VP35 Mutant Ebola Virus Lacks Virulence but Can Elicit Protective Immunity to Wild-Type Virus Challenge.

Authors:  Courtney Woolsey; Andrea R Menicucci; Robert W Cross; Priya Luthra; Krystle N Agans; Viktoriya Borisevich; Joan B Geisbert; Chad E Mire; Karla A Fenton; Allen Jankeel; Sneha Anand; Hideki Ebihara; Thomas W Geisbert; Ilhem Messaoudi; Christopher F Basler
Journal:  Cell Rep       Date:  2019-09-17       Impact factor: 9.423

3.  COVID-19 and Animal-Based Research.

Authors:  Jason S Villano
Journal:  Comp Med       Date:  2021-10-01       Impact factor: 0.982

4.  Biophysical and biological evaluation of optimized stapled peptide inhibitors of the linear ubiquitin chain assembly complex (LUBAC).

Authors:  Francisco Aguilar-Alonso; Amanda L Whiting; Ye Joon Kim; Federico Bernal
Journal:  Bioorg Med Chem       Date:  2017-12-05       Impact factor: 3.641

5.  Cranial Vena Cava Syndrome in Guinea Pigs with Chronic Jugular Vein Catheters.

Authors:  Timothy K Cooper; Russell A Byrum; Kurt Cooper; Lisa Evans DeWald; Nina M Aiosa; Irwin M Feuerstein; Marisa C St Claire
Journal:  Comp Med       Date:  2020-01-16       Impact factor: 0.982

Review 6.  The Collaborative Cross: A Systems Genetics Resource for Studying Host-Pathogen Interactions.

Authors:  Kelsey E Noll; Martin T Ferris; Mark T Heise
Journal:  Cell Host Microbe       Date:  2019-04-10       Impact factor: 21.023

7.  Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.

Authors:  Hualei Wang; Gary Wong; Wenjun Zhu; Shihua He; Yongkun Zhao; George F Gao; Songtao Yang; Xianzhu Xia; Xiangguo Qiu; Feihu Yan; Md Niaz Rahim; Yuhai Bi; Zirui Zhang; Keding Cheng; Hongli Jin; Zengguo Cao; Xuexing Zheng; Weiwei Gai; Jieying Bai; Weijin Chen; Yong Zou; Yuwei Gao
Journal:  J Virol       Date:  2019-02-19       Impact factor: 5.103

Review 8.  Pulmonary Involvement during the Ebola Virus Disease.

Authors:  Eleonora Lalle; Mirella Biava; Emanuele Nicastri; Francesca Colavita; Antonino Di Caro; Francesco Vairo; Simone Lanini; Concetta Castilletti; Martin Langer; Alimuddin Zumla; Gary Kobinger; Maria R Capobianchi; Giuseppe Ippolito
Journal:  Viruses       Date:  2019-08-24       Impact factor: 5.048

9.  Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir.

Authors:  Jason E Comer; Olivier Escaffre; Natasha Neef; Trevor Brasel; Terry L Juelich; Jennifer K Smith; Jeanon Smith; Birte Kalveram; David D Perez; Shane Massey; Lihong Zhang; Alexander N Freiberg
Journal:  Viruses       Date:  2019-02-03       Impact factor: 5.048

Review 10.  Syrian Hamster as an Animal Model for the Study on Infectious Diseases.

Authors:  Jinxin Miao; Louisa S Chard; Zhimin Wang; Yaohe Wang
Journal:  Front Immunol       Date:  2019-10-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.